title: Treatment of recurrent chronic hyperplastic sinusitis with nasal polyposis.
abstract: OBJECTIVE
  To demonstrate the long-term efficacy of intranasal furosemide, an inhibitor of the sodium chloride cotransporter channel at the basolateral surface of the respiratory epithelial cell, vs no therapeutic intervention vs intranasal mometasone furoate, a corticosteroid, in preventing relapses of chronic hyperplastic sinusitis with nasal polyposis.
  
  
  METHODS
  Randomized prospective controlled study. Patients were examined every 6 months during follow-up (range, 1-9 years).
  
  
  METHODS
  One hundred seventy patients with bilateral obstructive or minimally obstructive chronic hyperplastic sinusitis with nasal polyposis.
  
  
  METHODS
  All patients were surgically treated in the ENT Department, University of Siena Medical School. One month after surgery, group 1 patients (n = 97) started treatment with intranasal furosemide, group 2 (n = 40) received no therapeutic treatment, and group 3 (n = 33) were treated with mometasone.
  
  
  METHODS
  Clinical and instrumental evaluation of postoperative outcomes.
  
  
  RESULTS
  Seventeen (17.5%) of 97 patients in group 1, 12 (30.0%) of 40 patients in group 2, and 8 (24.2%) of 33 patients in group 3 experienced nasal polyposis relapses. We noted a prevalence of early-stage relapse in patients treated with furosemide or mometasone, whereas patients who did not receive any treatment experienced more severe grades of chronic hyperplastic sinusitis with nasal polyposis (P<.005).
  
  
  CONCLUSIONS
  Use of intranasal furosemide represents a valid therapeutic treatment in the prevention of chronic hyperplastic sinusitis with nasal polyposis.
authors.affiliation: ENT Department, University of Siena Medical School, Siena, Italy. Passali@unisi.it
authors.forename: Desiderio
authors.initials: D
authors.lastname: Passàli
authors.forename: Joel M
authors.initials: JM
authors.lastname: Bernstein
authors.forename: Francesco Maria
authors.initials: FM
authors.lastname: Passali
authors.forename: Valerio
authors.initials: V
authors.lastname: Damiani
authors.forename: Giulio Cesare
authors.initials: GC
authors.lastname: Passàli
authors.forename: Luisa
authors.initials: L
authors.lastname: Bellussi
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002908:Chronic Disease; D004232:Diuretics / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005665:Furosemide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D006965:Hyperplasia; D008297:Male; D008875:Middle Aged; D000068656:Mometasone Furoate; D015508:Nasal Obstruction / Q000150:complications / Q000188:drug therapy*; D009298:Nasal Polyps / Q000150:complications / Q000188:drug therapy*; D010256:Paranasal Sinuses / Q000473:pathology*; D011244:Pregnadienediols / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D055502:Secondary Prevention; D012852:Sinusitis / Q000150:complications / Q000188:drug therapy* / Q000517:prevention & control; D049992:Sodium Chloride Symporters; D027981:Symporters / Q000037:antagonists & inhibitors; D016896:Treatment Outcome
chemical_list: D000893:Anti-Inflammatory Agents; D004232:Diuretics; D011244:Pregnadienediols; D049992:Sodium Chloride Symporters; D027981:Symporters; D000068656:Mometasone Furoate; D005665:Furosemide